Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment
| العنوان: | Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment |
|---|---|
| المؤلفون: | Anna Calabrese, Paola Loli, Massimo Torlontano, Antonio Stigliano, Pasqualino Malandrino, Barbara Altieri, Paola Berchialla, Giuseppina De Filpo, Silvia Della Casa, Laura Saba, Filippo Ceccato, Soraya Puglisi, Giorgio Arnaldi, Paola Perotti, Letizia Canu, Chiara Simeoli, Carla Scaroni, Massimo Terzolo, Vittoria Basile, Giuseppe Reimondo, Salvatore Cannavò |
| المساهمون: | Puglisi, Soraya, Calabrese, Anna, Basile, Vittoria, Ceccato, Filippo, Scaroni, Carla, Simeoli, Chiara, Torlontano, Massimo, Cannavò, Salvatore, Arnaldi, Giorgio, Stigliano, Antonio, Malandrino, Pasqualino, Saba, Laura, Altieri, Barbara, Della Casa, Silvia, Perotti, Paola, Berchialla, Paola, De Filpo, Giuseppina, Canu, Letizia, Loli, Paola, Reimondo, Giuseppe, Terzolo, Massimo |
| المصدر: | Journal of Clinical Medicine; Volume 8; Issue 11; Pages: 1850 Journal of Clinical Medicine, Vol 8, Iss 11, p 1850 (2019) Journal of Clinical Medicine |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | mitotane, medicine.medical_specialty, Multivariate analysis, recurrence, lcsh:Medicine, 030209 endocrinology & metabolism, Lower risk, Gastroenterology, survival, Article, 03 medical and health sciences, 0302 clinical medicine, Interquartile range, Internal medicine, medicine, adrenocortical carcinoma, Adrenocortical carcinoma, Mitotane, adrenocortical carcinoma, mitotane, prognosis, recurrence, survival, Maintenance dose, business.industry, lcsh:R, Hazard ratio, General Medicine, medicine.disease, 030220 oncology & carcinogenesis, prognosis, business, Body mass index, prognosi, medicine.drug |
| الوصف: | Mitotane is used as a post-operative adjuvant treatment for patients with adrenocortical carcinoma. Monitoring of plasma mitotane concentrations is recommended, but we do not know what impact target concentrations have on patient outcome. To answer this question, we retrospectively analyzed patient records in the Lysosafe Online® database (HRA Pharma, France) for patients who were treated for ≥6 months and who had ≥3 measurements of plasma mitotane levels during follow-ups at 11 tertiary centers in Italy from 2005 to 2017. We identified 110 patients treated with adjuvant mitotane for a median of 46 months (IQR, interquartile range, 28−62) with a median maintenance dose of 2.0 g/day (IQR 1.5−2.5). Achievement of target mitotane concentrations (≥14 mg/L) required a median of 8 months (IQR 5−19). Female sex was associated inversely with the dose, while body mass index (BMI) was correlated positively. Multivariate analysis showed that the Ki67 index and time to achieve the target range of plasma mitotane were independent predictors of recurrence-free survival (RFS). In a separate multivariate model, considering only the maintenance phase (month 7 to month 36, M7−M36) of treatment, the time in the target range of plasma mitotane was associated with a significantly lower risk of recurrence (Hazard Ratio, HR = 0.93; 0.88−0.98, p < 0.01). The prognostic implications of the time in target range and the time needed to reach target mitotane concentrations support the use of mitotane monitoring and may inform practice. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f43edd86d27769dafec8c5146de404cTest http://hdl.handle.net/2318/1718782Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....8f43edd86d27769dafec8c5146de404c |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |